Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?

CVS Health's Pharmacy & Consumer Wellness segment showed strong growth with operating income up 10.2% year-over-year to $1.48 billion in Q2 2026, supported by higher prescription volumes and improved margins. The company raised its 2026 operating income outlook for the segment by $220 million. CVS is expanding AI tools including Health100 and Claims Assist Manager to improve efficiency and customer service. However, reimbursement pressure, regulatory scrutiny, and insufficient Medicare Advantage payment updates remain key headwinds. With a discounted valuation (P/S of 0.29X vs. industry average 0.53X), Zacks recommends current holders maintain positions while prospective investors wait for a more favorable entry point.